DIABETES, A RISING PUBLIC HEALTH ISSUE
According to the World Health Organization (WHO), 8,5% of adults 18 years and older worldwide were living with diabetes in 2014. What’s more, the disease was responsible for some 1.6 million deaths in 2015. Type 2 diabetes accounts for 90% of cases worldwide.
This translates into over 422 million diabetics across the globe.
Diabetes poses more of a public health concern than ever before, especially in developing countries. This is largely due to the rise of obesity and sedentary lifestyles. No less than three-quarters of diabetics live in low- and middle-income countries.
Diabetes is essentially a chronic disease caused by either a lack of insulin – the hormone regulating blood sugar (glucose) – in the body (type 1) or the inability of the body to use the insulin the pancreas produces (type 2). These both lead to increased blood sugar, or hyperglycemia. The effects of diabetes are numerous and severe: increased risk of cardiovascular diseases, kidney failure, foot ulcer, blindness.
SANOFI ON THE FRONTLINE
Sanofi is committed to working to address the diabetes public health concern worldwide through its integrated treatments and medical devices.
Sanofi has invested more than €1 billion over 10 years in its largest industrial complex in the world just outside Frankfurt, Germany. Moreover, it recently inaugurated a €75 million high-tech building designed to produce a new type of insulin to treat around 6 million patients. It houses the most modern technology, enabling Sanofi to achieve the highest sterility standards in the industry.
Sanofi is actively involved in civil society initiatives around the world and partnerships with local health authorities and NGOs to improve the diagnosis of diabetes and patient knowledge as well as to train health professionals.